Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
15.60
+0.09 (0.58%)
Oct 14, 2024, 4:00 PM EDT - Market closed

Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases.

The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders.

In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease.

The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.

Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics, Inc.
Neumora Therapeutics logo
Country United States
Founded 2019
IPO Date Sep 15, 2023
Industry Biotechnology
Sector Healthcare
Employees 124
CEO Henry Gosebruch

Contact Details

Address:
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
United States
Phone 857 760 0900
Website neumoratx.com

Stock Details

Ticker Symbol NMRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001885522
CUSIP Number 640979100
ISIN Number US6409791000
Employer ID 84-4367680
SIC Code 2836

Key Executives

Name Position
Henry O. Gosebruch President, Chief Executive Officer and Director
Paul L. Berns Co-Founder and Executive Chairman
Jason G. Duncan Chief Legal Officer
Robert Lenz M.D., Ph.D. Head of Research and Development
Carol Suh Co-Founder and Chief Operating Officer
Dr. Robert Michael Poole FACP, M.D. Co-Founder and Advisor
Dr. Joshua Pinto Ph.D. Chief Financial Officer
Michael Lee Milligan Principal Accounting Officer
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer
Nicholas Brandon Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 10, 2024 144 Filing
Oct 9, 2024 144 Filing
Oct 1, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Sep 18, 2024 144 Filing
Sep 17, 2024 144 Filing
Sep 12, 2024 144 Filing
Aug 22, 2024 144 Filing
Aug 6, 2024 10-Q Quarterly Report
Aug 6, 2024 8-K Current Report
Jul 8, 2024 SCHEDULE 13G Filing